Compare · BDMD vs DXCM
BDMD vs DXCM
Side-by-side comparison of Baird Medical Investment Holdings Ltd (BDMD) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDMD and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 1303.5x BDMD ($25.4M).
- Over the past year, BDMD is down 62.3% and DXCM is up 29.2% - DXCM leads by 91.5 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 5 for BDMD).
- DXCM has more recent analyst coverage (25 ratings vs 0 for BDMD).
- Company
- Baird Medical Investment Holdings Ltd
- DexCom Inc.
- Price
- $0.58+1.98%
- $86.05-1.93%
- Market cap
- $25.4M
- $33.10B
- 1M return
- -45.20%
- -2.13%
- 1Y return
- -62.28%
- +29.24%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 5
- 6
- Recent ratings
- 0
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BDMD
- Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026
- SEC Form SCHEDULE 13G filed by Baird Medical Investment Holdings Ltd
- SEC Form 6-K filed by Baird Medical Investment Holdings Ltd
- SEC Form 6-K filed by Baird Medical Investment Holdings Ltd
- SEC Form 424B5 filed by Baird Medical Investment Holdings Ltd
- Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology
- SEC Form 6-K filed by Baird Medical Investment Holdings Ltd
- Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026
- Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer